Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 2

6(85.7%)

Phase 3

1(14.3%)

7Total

Phase 2(6)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03970447Phase 2Recruiting

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Role: lead

NCT05948579Phase 2Not Yet Recruiting

Department of Defense PTSD Adaptive Platform Trial - Intervention B - Vilazodone

Role: lead

NCT05422612Phase 2Recruiting

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Role: lead

NCT06816433Phase 2Not Yet Recruiting

Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

Role: lead

NCT05948553Phase 2Recruiting

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

Role: lead

NCT05948540Phase 2Recruiting

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Role: lead

NCT02735707Phase 3Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Role: collaborator

All 7 trials loaded